TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18444867

Group type: EXPERIMENTAL
Intervention: First-line ART regimens including zidovudine-lamivudine plus tenofovir disoproxil fumarate (74% of patients), nevirapine (16%), and abacavir (9%)
Number of subjects: 3316

Group type: EXPERIMENTAL
Intervention: First-line ART regimens
Number of subjects: 3316
Study: 18794178

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Etanercept plus sulfasalazine (2-3 g/day)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 254
Study: 15786440

Group type: EXPERIMENTAL
Intervention: Salbutamol via MDI-spacer (2 puffs, 100 microg/puff)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Jet nebulizer (0.15 mg/kg salbutamol respiratory solution)
Number of subjects: 47
Study: 11976156

Group type: EXPERIMENTAL
Intervention: High-fiber diet (4 servings/d of foods containing beta-glucan or psyllium delivering 8 g/d more soluble fiber)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control diet (low-fat, low-cholesterol)
Number of subjects: 68
Study: 9758392

Group type: EXPERIMENTAL
Intervention: Language task
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Face-recognition task
Number of subjects: 11
Study: 8111572

Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 21
Study: 3261614

Group type: EXPERIMENTAL
Intervention: Synthetic oxytocin and ergotamine intramuscularly (10 women)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment (15 women)
Number of subjects: 25
Study: 11318787

Group type: EXPERIMENTAL
Intervention: Acipimox (A) 250 mg, orally, administered at -210 minutes and -60 minutes
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GHRH (100 microg, iv, 0 minutes)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GHRH plus Acipimox (A)
Number of subjects: 6
Study: 30107471

Group type: EXPERIMENTAL
Intervention: Reciprocity prime
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 420
Study: 30412513

Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 27379793

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (8 g kg(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low carbohydrate diet (3 g kg(‐1))
Number of subjects: 12
Study: 24287674

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP) and kyphoplasty (PKP)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 290
Study: 22299124

Group type: EXPERIMENTAL
Intervention: NitrAdine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 19713256

Group type: EXPERIMENTAL
Intervention: DEX 0.5 microg/kg
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: DEX 1 microg/kg
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: DEX (both doses)
Number of subjects: 326
Study: 18631245

Group type: EXPERIMENTAL
Intervention: 500 mg azithromycin once a day for 3 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15921833

Group type: EXPERIMENTAL
Intervention: Vertical torque during slow arm-raising movements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vertical torque during rapid arm-raising movements
Number of subjects: 20
Study: 12022709

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg o.d.
Number of subjects: 983

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 983
Study: 10029593

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (LDMTX)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX)
Number of subjects: 121
Study: 9454116

Group type: EXPERIMENTAL
Intervention: Crystallization test with cupric chloride solution in patients with head and neck neoplasms
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 31
Study: 2181603

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 3335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3335
Study: 343256

Group type: EXPERIMENTAL
Intervention: Cefazolin and cephalexin (prophylactic antibiotics)
Number of subjects: 0
Study: 31050026

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention (interactive, home visiting curriculum)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control home visiting curriculum
Number of subjects: 102
Study: 29505146

Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) measurements at 37.5±0.7 weeks (Time 1) and 41.0±0.7 weeks (Time 2) postmenstrual age
Number of subjects: 22
Study: 27410176

Group type: EXPERIMENTAL
Intervention: Testicular warming in a 43 °C water bath for 10 consecutive days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Testicular warming in a 43 °C water bath once every 3 days
Number of subjects: 20
Study: 24756462

Group type: EXPERIMENTAL
Intervention: Test formulation of ibandronic acid (T)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Bonviva(®) (R) - first dosing
Number of subjects: 153

Group type: COMPARATOR
Intervention: Bonviva(®) (R) - second dosing
Number of subjects: 153
Study: 22059618

Group type: EXPERIMENTAL
Intervention: Intervention based on the Theory of Planned Behavior (TPB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: General control condition
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mere measurement control condition
Number of subjects: 45
Study: 20144471

Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgical staging
Number of subjects: 275

Group type: COMPARATOR
Intervention: Traditional laparoscopic surgical staging
Number of subjects: 275
Study: 17625432

Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg/day, orally)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 15831782

Group type: EXPERIMENTAL
Intervention: R1518 (levovirin valinate hydrochloride)
Number of subjects: 0
Study: 27398636

Group type: EXPERIMENTAL
Intervention: 123I-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy
Number of subjects: 59

Group type: COMPARATOR
Intervention: 123I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) SPECT
Number of subjects: 59
Study: 11197445

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/day)
Number of subjects: 4495

Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg/day)
Number of subjects: 4495
Study: 9552780

Group type: EXPERIMENTAL
Intervention: Remifentanil (6 microg/kg/h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Propofol (3 mg/kg/h)
Number of subjects: 28
Study: 7871917

Group type: EXPERIMENTAL
Intervention: Credé-prophylaxis with Argentum nitricum
Number of subjects: 40

Group type: COMPARATOR
Intervention: No Credé-prophylaxis
Number of subjects: 40
Study: 3421279

Group type: EXPERIMENTAL
Intervention: Antenatal vitamin K1 (10 mg intramuscularly every 5 days until delivery)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No antenatal vitamin K1 therapy
Number of subjects: 92
Study: 31138165

Group type: EXPERIMENTAL
Intervention: Family-based multimedia intervention including PowerPoint presentation, video clip, and health information booklet.
Number of subjects: 320

Group type: COMPARATOR
Intervention: Wait-list control group receiving the intervention after post-intervention data collection.
Number of subjects: 320
Study: 28696135

Group type: EXPERIMENTAL
Intervention: Solution Focused Brief Therapy (SFBT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no psychotherapy)
Number of subjects: 62
Study: 25855751

Group type: EXPERIMENTAL
Intervention: Pay-for-reporting intervention with monthly incentive fees and chart audits every 6 months.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 11
Study: 22895620

Group type: EXPERIMENTAL
Intervention: Memory self-efficacy (MSE) training program
Number of subjects: 153

Group type: COMPARATOR
Intervention: Peer support program (control group)
Number of subjects: 153
Study: 21970511

Group type: EXPERIMENTAL
Intervention: Sedentary behavior intervention (SB-I)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (PA-I)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Combined sedentary behavior and physical activity intervention (SB+PA-I)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Current practice control (C)
Number of subjects: 600
Study: 18394088

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16537663

Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg daily)
Number of subjects: 20078

Group type: COMPARATOR
Intervention: Enoxaparin (1 mg per kilogram of body weight twice daily)
Number of subjects: 20078

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 20078

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 20078
Study: 12773061

Group type: EXPERIMENTAL
Intervention: rhEPO 1000 units/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11043855

Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 22
Study: 9358570

Group type: EXPERIMENTAL
Intervention: Coelocentesis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (planned termination)
Number of subjects: 20
Study: 8129540

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg + Nifedipine 20 mg (AN)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 57
Study: 3524837

Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) at total doses less than 902 mg/m2
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) at total doses greater than 902 mg/m2
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) at total doses exceeding 1400 mg/m2
Number of subjects: 289

Group type: COMPARATOR
Intervention: Misonidazole administration
Number of subjects: 289
Study: 31301031

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 60
Study: 29806405

Group type: EXPERIMENTAL
Intervention: Mini-subvastus approach
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 94
Study: 26514145

Group type: EXPERIMENTAL
Intervention: ALFIT training (8-week equipment-based progressive resistance training program)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Routine program of the day hospital (Control group)
Number of subjects: 38
Study: 25131034

Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapeutic program including diaphragmatic breathing exercises, diaphragmatic isometric exercise, Threshold IMT, lifting the upper limbs with a bat, and strengthening the abdominals
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 42
Study: 22316106

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 2269

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 2269

Group type: COMPARATOR
Intervention: Allopurinol (200 mg or 300 mg depending on renal function)
Number of subjects: 2269
Study: 20649528

Group type: EXPERIMENTAL
Intervention: High volume/low concentration solution of ropivacaine (20 ml, 0.5%)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low volume/high concentration solution of ropivacaine (10 ml, 1%)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High volume/low concentration group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low volume/high concentration group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Number of subjects: 48
Study: 17983398

Group type: EXPERIMENTAL
Intervention: Intensive follow-up (n=58) including diagnostic laboratory tests and imaging.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard clinical follow-up (n=63) with annual mammography.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard clinical follow-up (n=63)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intensive follow-up (n=58)
Number of subjects: 121
Study: 15991756

Group type: EXPERIMENTAL
Intervention: Pharmacist-guided education and monitoring (PGEM) through three monthly telephone calls
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual pharmacist's care
Number of subjects: 63
Study: 12509594

Group type: EXPERIMENTAL
Intervention: SpO2 of 94% and RR of 50/min
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: SpO2 of 94% and RR of 65/min
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: SpO2 of 92% and RR of 50/min
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: SpO2 of 92% and RR of 65/min
Number of subjects: 519
Study: 11221808

Group type: EXPERIMENTAL
Intervention: Physical training (6-week guided training in hospital, followed by 6 weeks at home, and 12 weeks at home without supervision)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 58
Study: 7852918

Group type: EXPERIMENTAL
Intervention: Blood donations (venesection)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no blood donations)
Number of subjects: 14
Study: 1777051

Group type: EXPERIMENTAL
Intervention: Salbutamol CR
Number of subjects: 83

Group type: COMPARATOR
Intervention: Theophylline L.A.
Number of subjects: 83
Study: 7143496

Group type: EXPERIMENTAL
Intervention: Polyurethane casts
Number of subjects: 46

Group type: COMPARATOR
Intervention: Plaster-of-Paris braces
Number of subjects: 46
Study: 6362597

Group type: EXPERIMENTAL
Intervention: Immune globulin (0.06 mL/kg of body weight)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (0.06 mL/kg of body weight)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Immune globulin (twice the dose of the first group)
Number of subjects: 60
Study: 28460586

Group type: EXPERIMENTAL
Intervention: [6S]-5-methyltetrahydrofolate (400 μg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Folic acid (400 μg/d)
Number of subjects: 40
Study: 27525386

Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 25407792

Group type: EXPERIMENTAL
Intervention: Mediterranean diet using olive oil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control low-fat diet
Number of subjects: 24
Study: 22849308

Group type: EXPERIMENTAL
Intervention: 10 mL/kg IV fluid administration
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 30 mL/kg IV fluid administration
Number of subjects: 42

Group type: COMPARATOR
Intervention: 2 mL/kg IV fluid administration (control group)
Number of subjects: 42
Study: 20705558

Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus zoledronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 0
Study: 18502360

Group type: COMPARATOR
Intervention: 0.0 mg intrathecal morphine (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.2 mg intrathecal morphine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.3 mg intrathecal morphine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.4 mg intrathecal morphine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.1 to 0.4 mg)
Number of subjects: 100
Study: 15985482

Group type: EXPERIMENTAL
Intervention: 1-yr low-energy diet
Number of subjects: 150
Study: 11443511

Group type: EXPERIMENTAL
Intervention: 500 mg HCA
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 500 mg HCA and 3 g MCT
Number of subjects: 11

Group type: COMPARATOR
Intervention: No supplementation (PLA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All treatments (PLA, HCA, HCA+MCT)
Number of subjects: 11
Study: 9778328

Group type: EXPERIMENTAL
Intervention: GnRHa + estrogen/progestogen add-back therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: GnRHa alone
Number of subjects: 2
Study: 7820145

Group type: EXPERIMENTAL
Intervention: rHuEPO by subcutaneous route, initial doses of 20U/kg/dialysis, mean correction dose of 65U/kg/dialysis, maintenance dose of 51U/kg/dialysis
Number of subjects: 12
Study: 2458159

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plasma protein fraction (PPF)
Number of subjects: 40
Study: 29949492

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoid plus LABA (combination therapy)
Number of subjects: 36010

Group type: COMPARATOR
Intervention: Inhaled glucocorticoid alone (control)
Number of subjects: 36010
Study: 26549852

Group type: EXPERIMENTAL
Intervention: Enhanced psychosocial support (counseling and psychosocial interventions by a palliative care nurse and social worker)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Enhanced psychosocial support
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard renal care (control)
Number of subjects: 29
Study: 25282874

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD), skin care, bandaging, and remedial exercises
Number of subjects: 57

Group type: COMPARATOR
Intervention: Skin care, bandaging, and remedial exercises
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both treatment groups (MLD and control)
Number of subjects: 57
Study: 22819803

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2000 mg taurine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine + 50 g glucose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2000 mg taurine + 50 g glucose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Salivary cortisol and heart rate
Number of subjects: 48
Study: 22128442

Group type: EXPERIMENTAL
Intervention: diclofenac-cholestyramine + uridine + cytidine + vitamin B12 (Group DN)
Number of subjects: 81

Group type: COMPARATOR
Intervention: uridine + cytidine + vitamin B12 (Group NB)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study: 17493196

Group type: EXPERIMENTAL
Intervention: ALN 70 mg once a week plus calcitriol (1,25D3) 0.5 microg daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: ALN 70 mg once a week alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (ALN alone and ALN plus calcitriol)
Number of subjects: 120
Study: 15664872

Group type: EXPERIMENTAL
Intervention: Osteotomy by sawing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Osteotomy by milling
Number of subjects: 80
Study: 12198013

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (0.5 mmol.kg(-1).d(-1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (alanine)
Number of subjects: 16
Study: 9609267

Group type: EXPERIMENTAL
Intervention: Oestradiol (2 mg daily) for 20 to 24 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo for 20 to 24 weeks
Number of subjects: 28
Study: 7639104

Group type: EXPERIMENTAL
Intervention: Transcutaneous 17‐beta‐estradiol (50 micrograms daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cyclical intravenous clodronate (200 mg/month iv infusion)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 124
Study: 2560289

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (duration: 6 months)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Normotensive controls (no treatment)
Number of subjects: 201
Study: 791563

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) at doses of 0, 150, or 500 mug/kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Secobarbital (150 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Secobarbital (150 mg/70 kg) with CBD pretreatment
Number of subjects: 6
Study: 31770194

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with LED (660 and 850 nm with 6 J per point for extraoral device; 660 nm with 2 J per point for intraoral device)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (simulated irradiation with devices kept off)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with LED
Number of subjects: 72
Study: 29513547

Group type: EXPERIMENTAL
Intervention: Loaded condition (valgus load)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unloaded condition (at rest)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Loaded-contracted condition (maximal grip contraction under valgus load)
Number of subjects: 22
Study: 26729384

Group type: EXPERIMENTAL
Intervention: Feedback on inhaler technique and adherence from the audio recording device over a 3-month period.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Training in inhaler technique and strategies to promote adherence (no feedback from the device).
Number of subjects: 220
Study: 24368554

Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 16
Study: 22221171

Group type: EXPERIMENTAL
Intervention: Mirtazapine (45 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20638340

Group type: EXPERIMENTAL
Intervention: Atosiban (37.5 mg intravenous administration before embryo transfer)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 180
Study: 17596728

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS-15)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 62
Study: 16334434

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 93

Group type: COMPARATOR
Intervention: Open fundoplication (Laparotomy)
Number of subjects: 93
Study: 11926622

Group type: EXPERIMENTAL
Intervention: Symptom-time peak expiratory flow rate (PEFR) monitoring
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Daily PEFR monitoring
Number of subjects: 168

Group type: COMPARATOR
Intervention: Subjective symptom evaluation
Number of subjects: 168
Study: 10406235

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408